Drugs / Fluzone High-Dose Quadrivalent
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05052697 | Sep 2021 → Jan 2023 | influenza | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone High-Dose Quadrivalent | “quadrivalent influenza vaccine (QIV; Fluzone High-Dose Quadrivalent, Sanofi Pasteur)” PMID 40333267 ↗ Apr 2025 |
| Known as | QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05052697 ↗ |
| Modality | Vaccine | “quadrivalent influenza vaccine (QIV; Fluzone High-Dose Quadrivalent, Sanofi Pasteur)” PMID 40333267 ↗ Apr 2025 |